Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Alethia to start a clinical trial of AB-16B5 in combination with docetaxel in subjects with metastatic non-small cell lung cancer who have experienced disease progression following treatment with a platinum-containing doublet treatment and an anti-PD1 or PD-L1.
Lead Product(s): AB-16B5,Docetaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020